Abbott India Ltd reported a consolidated net profit of Rs 4.15 billion for the September 2025 quarter, supported by operational revenue of Rs 17.57 billion. The company’s performance reflects strong domestic demand, portfolio expansion, and disciplined cost management across its pharmaceutical and healthcare segments.
Abbott India Ltd, a leading pharmaceutical and healthcare company, announced its financial results for the second quarter of FY2025–26, showcasing solid growth across key metrics. The company posted consolidated revenue from operations of Rs 17.57 billion and a net profit of Rs 4.15 billion for the quarter ended September 30, 2025.
The results highlight Abbott’s continued leadership in therapeutic areas such as gastroenterology, neurology, and women’s health. Strong demand from the domestic market, coupled with effective pricing strategies and operational efficiencies, contributed to the healthy profit margins.
Management reaffirmed its focus on innovation, patient-centric solutions, and digital outreach to strengthen engagement with healthcare professionals. The company also emphasized its commitment to expanding access to essential medicines and enhancing supply chain resilience.
Major Takeaways
- Q2 FY2025–26 consolidated revenue: Rs 17.57 billion
- Net profit for the quarter: Rs 4.15 billion
- Strong growth in gastroenterology and women’s health segments
- Domestic demand and pricing strategies supported margins
- Continued focus on innovation and digital outreach
Sources: Reuters, Business Standard, Abbott India Investor Filings, Economic Times